Thierry Levade

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8997000/publications.pdf

Version: 2024-02-01

57	2,734	186265	189892
papers	citations	28 h-index	50 g-index

59	59	59	3565
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments. International Journal of Molecular Sciences, 2017, 18, 441.	4.1	497
2	Spinal Muscular Atrophy Associated with Progressive Myoclonic Epilepsy Is Caused by Mutations in ASAH1. American Journal of Human Genetics, 2012, 91, 5-14.	6.2	250
3	Recommendations on the diagnosis and management of Niemann-Pick disease type C. Molecular Genetics and Metabolism, 2009, 98, 152-165.	1.1	210
4	Sphingolipids as modulators of cancer cell death: Potential therapeutic targets. Biochimica Et Biophysica Acta - Biomembranes, 2006, 1758, 2104-2120.	2.6	116
5	Elevation of glucosylceramide in multidrug-resistant cancer cells and accumulation in cytoplasmic droplets. International Journal of Cancer, 2001, 94, 157-165.	5.1	110
6	Disruption of Sphingosine 1-Phosphate Lyase Confers Resistance to Chemotherapy and Promotes Oncogenesis through Bcl-2/Bcl-xL Upregulation. Cancer Research, 2009, 69, 9346-9353.	0.9	103
7	The natural marine anhydrophytosphingosine, Jaspine B, induces apoptosis in melanoma cells by interfering with ceramide metabolism. Biochemical Pharmacology, 2009, 78, 477-485.	4.4	99
8	Acid ceramidase deficiency: Farber disease and SMA-PME. Orphanet Journal of Rare Diseases, 2018, 13, 121.	2.7	91
9	Systemic ceramide accumulation leads to severe and varied pathological consequences. EMBO Molecular Medicine, 2013, 5, 827-842.	6.9	90
10	IL-6 Deficiency Attenuates Murine Diet-Induced Non-Alcoholic Steatohepatitis. PLoS ONE, 2009, 4, e7929.	2.5	75
11	Acid Ceramidase Expression Modulates the Sensitivity of A375 Melanoma Cells to Dacarbazine. Journal of Biological Chemistry, 2011, 286, 28200-28209.	3.4	71
12	Functions of sphingolipid metabolism in mammals â€" Lessons from genetic defects. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2008, 1781, 145-183.	2.4	62
13	Synthesis of a Novel Ceramide Analogue and its Use in a High-Throughput Fluorogenic Assay for Ceramidases. ChemBioChem, 2007, 8, 642-648.	2.6	53
14	A simple fluorogenic method for determination of acid ceramidase activity and diagnosis of Farber disease. Journal of Lipid Research, 2010, 51, 3542-3547.	4.2	53
15	PNPLA1 defects in patients with autosomal recessive congenital ichthyosis and KO mice sustain PNPLA1 irreplaceable function in epidermal omega-O-acylceramide synthesis and skin permeability barrier. Human Molecular Genetics, 2017, 26, 1787-1800.	2.9	47
16	The absence of functional glucosylceramide synthase does not sensitize melanoma cells for anticancer drugs. FASEB Journal, 2003, 17, 1144-1146.	0.5	45
17	Danon's disease (X-linked vacuolar cardiomyopathy and myopathy): a case with a novel Lamp-2 gene mutation. Neuromuscular Disorders, 2002, 12, 882-885.	0.6	41
18	Acid Ceramidase Deficiency in Mice Results in a Broad Range of Central Nervous System Abnormalities. American Journal of Pathology, 2017, 187, 864-883.	3.8	41

#	Article	IF	Citations
19	The nonlysosomal Î²â€glucosidase GBA2 promotes endoplasmic reticulum stress and impairs tumorigenicity of human melanoma cells. FASEB Journal, 2013, 27, 489-498.	0.5	39
20	Glucosylceramidases and malignancies in mammals. Biochimie, 2016, 125, 267-280.	2.6	36
21	Acid Ceramidase Deficiency is characterized by a unique plasma cytokine and ceramide profile that is altered by therapy. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2017, 1863, 386-394.	3.8	35
22	Downregulation of sphingosine kinase-1 induces protective tumor immunity by promoting M1 macrophage response in melanoma. Oncotarget, 2016, 7, 71873-71886.	1.8	35
23	Autologous Transplantation of Lentivector/Acid Ceramidaseâ€“Transduced Hematopoietic Cells in Nonhuman Primates. Human Gene Therapy, 2011, 22, 679-687.	2.7	34
24	Natural disease history and characterisation of SUMF1 molecular defects in ten unrelated patients with multiple sulfatase deficiency. Orphanet Journal of Rare Diseases, 2015, 10, 31.	2.7	33
25	In vivo delivery of human acid ceramidase via cord blood transplantation and direct injection of lentivirus as novel treatment approaches for Farber disease. Molecular Genetics and Metabolism, 2008, 95, 133-141.	1.1	32
26	Acid ceramidase deficiency associated with spinal muscular atrophy with progressive myoclonic epilepsy. Neuromuscular Disorders, 2015, 25, 959-963.	0.6	32
27	Retrovirus-Mediated Correction of the Metabolic Defect in Cultured Farber Disease Cells. Human Gene Therapy, 1999, 10, 1321-1329.	2.7	30
28	Human genetic disorders of sphingolipid biosynthesis. Journal of Inherited Metabolic Disease, 2015, 38, 65-76.	3.6	29
29	Chronic lung injury and impaired pulmonary function in a mouse model of acid ceramidase deficiency. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2018, 314, L406-L420.	2.9	26
30	A simple method for screening for Farber disease on cultured skin fibroblasts. Clinica Chimica Acta, 1996, 245, 61-71.	1.1	25
31	Molecular basis of acid ceramidase deficiency in a neonatal form of Farber disease: Identification of the first large deletion in ASAH1 gene. Molecular Genetics and Metabolism, 2013, 109, 276-281.	1.1	25
32	Monogenic neurological disorders of sphingolipid metabolism. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2015, 1851, 1040-1051.	2.4	25
33	Targeting the Sphingosine 1-Phosphate Axis Exerts Potent Antitumor Activity in BRAFi-Resistant Melanomas. Molecular Cancer Therapeutics, 2019, 18, 289-300.	4.1	25
34	Farber lipogranulomatosis with predominant joint involvement mimicking juvenile idiopathic arthritis. Journal of Inherited Metabolic Disease, 2013, 36, 1079-1080.	3.6	23
35	C-Alkyl 5-membered ring imino sugars as new potent cytotoxic glucosylceramide synthase inhibitors. Organic and Biomolecular Chemistry, 2006, 4, 4437-4439.	2.8	22
36	Sphingomyelin Synthase 1 (SMS1) Downregulation Is Associated With Sphingolipid Reprogramming and a Worse Prognosis in Melanoma. Frontiers in Pharmacology, 2019, 10, 443.	3.5	22

#	Article	IF	Citations
37	Brief Report: Peripheral Osteolysis in Adults Linked to ASAH1 (Acid Ceramidase) Mutations: A New Presentation of Farber's Disease. Arthritis and Rheumatology, 2016, 68, 2323-2327.	5.6	17
38	Highly Regioselective Oxirane Ringâ€Opening of a Versatile Epoxypyrrolidine Precursor of New Iminoâ€Sugarâ€Based Sphingolipid Mimics. European Journal of Organic Chemistry, 2009, 2009, 2474-2489.	2.4	15
39	Danon disease: Further clinical and molecular heterogeneity. Muscle and Nerve, 2009, 39, 837-844.	2.2	15
40	New Insights into the Role of Sphingolipid Metabolism in Melanoma. Cells, 2020, 9, 1967.	4.1	15
41	Allogeneic hematopoietic cell transplantation in Farber disease. Journal of Inherited Metabolic Disease, 2019, 42, 286-294.	3.6	13
42	Are Glucosylceramide-Related Sphingolipids Involved in the Increased Risk for Cancer in Gaucher Disease Patients? Review and Hypotheses. Cancers, 2020, 12, 475.	3.7	13
43	Danon disease: intrafamilial phenotypic variability related to a novel LAMP-2 mutation. Journal of Inherited Metabolic Disease, 2011, 34, 515-522.	3.6	12
44	Concise asymmetric synthesis of new enantiomeric C-alkyl pyrrolidines acting as pharmacological chaperones against Gaucher disease. Organic and Biomolecular Chemistry, 2020, 18, 7852-7861.	2.8	12
45	First Report of a Patient with MPS Type VII, Due to Novel Mutations in GUSB, Who Underwent Enzyme Replacement and Then Hematopoietic Stem Cell Transplantation. International Journal of Molecular Sciences, 2019, 20, 5345.	4.1	10
46	Selective Targeting of the Interconversion between Glucosylceramide and Ceramide by Scaffold Tailoring of Iminosugar Inhibitors. Molecules, 2019, 24, 354.	3.8	5
47	Allogeneic hematopoietic cell transplantation in Farber disease. Journal of Inherited Metabolic Disease, 0, , .	3.6	4
48	Spinal muscular atrophy and Farber disease due to ASAH1 variants: A case report. American Journal of Medical Genetics, Part A, 2020, 182, 2369-2371.	1.2	4
49	Basics of Sphingolipid Metabolism and Signalling. , 2015, , 1-20.		4
50	A case of <scp>ASAH1</scp>â€related pure SMA evolving into adultâ€onset Farber disease. Clinical Genetics, 2021, 100, 234-235.	2.0	3
51	Disorders of Sphingolipid Synthesis, Sphingolipidoses, Niemann-Pick Disease Type C and Neuronal Ceroid Lipofuscinoses. , 2016, , 551-575.		3
52	Inherited monogenic defects of ceramide metabolism: Molecular bases and diagnoses. Clinica Chimica Acta, 2019, 495, 457-466.	1.1	2
53	Dysregulation of Sphingolipid Metabolism in Melanoma: Roles in Pigmentation, Cell Survival and Tumor Progression. , 2015, , 123-139.		2
54	Disorders of Sphingolipid Synthesis, Sphingolipidoses, Niemann-Pick Disease Type C and Neuronal Ceroid Lipofuscinoses. , 2022, , 735-764.		1

#	Article	IF	Citations
55	A diagnosis of progressive myoclonic ataxia guided by blood biomarkers. Parkinsonism and Related Disorders, 2022, 94, 124-126.	2.2	0
56	Role of Sphingolipids in Death Receptor Signalling. Resistance To Targeted Anti-cancer Therapeutics, 2017, , 229-245.	0.1	0
57	Pregnancy outcome in Refsum disease: Affected fetuses and children born to an affected mother. JIMD Reports, 2019, 46, 11-15.	1.5	0